Bank of New York Mellon Corp Sells 2,549 Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

Bank of New York Mellon Corp trimmed its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,761 shares of the biopharmaceutical company’s stock after selling 2,549 shares during the quarter. Bank of New York Mellon Corp owned 0.30% of Intercept Pharmaceuticals worth $4,368,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ICPT. State of Wisconsin Investment Board grew its stake in Intercept Pharmaceuticals by 221.0% during the 4th quarter. State of Wisconsin Investment Board now owns 11,689 shares of the biopharmaceutical company’s stock valued at $683,000 after purchasing an additional 8,047 shares in the last quarter. First Trust Advisors LP grew its stake in Intercept Pharmaceuticals by 101.5% during the 4th quarter. First Trust Advisors LP now owns 605,454 shares of the biopharmaceutical company’s stock valued at $35,371,000 after purchasing an additional 304,999 shares in the last quarter. Retirement Systems of Alabama acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter worth approximately $2,039,000. Candriam Luxembourg S.C.A. grew its position in shares of Intercept Pharmaceuticals by 113.3% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 32,000 shares of the biopharmaceutical company’s stock worth $1,869,000 after acquiring an additional 17,000 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter worth approximately $346,000. Institutional investors own 64.31% of the company’s stock.

How to Become a New Pot Stock Millionaire

In related news, Director Keith Michael Gottesdiener purchased 1,171 shares of Intercept Pharmaceuticals stock in a transaction on Monday, April 9th. The stock was bought at an average price of $64.00 per share, with a total value of $74,944.00. Following the completion of the transaction, the director now directly owns 5,001 shares of the company’s stock, valued at $320,064. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Mark Pruzanski purchased 7,812 shares of Intercept Pharmaceuticals stock in a transaction on Monday, April 9th. The stock was bought at an average cost of $64.00 per share, with a total value of $499,968.00. Following the transaction, the chief executive officer now directly owns 11,642 shares of the company’s stock, valued at $745,088. The disclosure for this purchase can be found here. Insiders acquired 399,608 shares of company stock worth $25,574,912 in the last 90 days. Corporate insiders own 4.50% of the company’s stock.

Shares of ICPT stock opened at $74.10 on Tuesday. Intercept Pharmaceuticals Inc has a 1-year low of $51.05 and a 1-year high of $135.59. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 21.71. The firm has a market cap of $2,150.49, a PE ratio of -5.15 and a beta of -1.81.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The firm had revenue of $37.69 million during the quarter, compared to analysts’ expectations of $39.01 million. During the same quarter last year, the firm earned ($4.84) EPS. The business’s revenue for the quarter was up 173.1% compared to the same quarter last year. equities research analysts anticipate that Intercept Pharmaceuticals Inc will post -12.59 EPS for the current year.

Several brokerages have recently commented on ICPT. ValuEngine lowered Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Goldman Sachs lowered Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a research report on Wednesday, February 7th. BidaskClub upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 25th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, February 19th. Finally, Citigroup set a $74.00 price objective on Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, December 21st. Four investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $128.90.

ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Sells 2,549 Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT)” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://ledgergazette.com/2018/04/17/bank-of-new-york-mellon-corp-reduces-holdings-in-intercept-pharmaceuticals-inc-icpt.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply